Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders

European Psychiatry

Volumn 22, Issue 3, 2007, Pages 177-187

  König, Hans Helmut ^a   Roick, Christiane ^a   Angermeyer, Matthias C ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

EQ 5D; EuroQol; Quality of life; Schizophrenia; Validity

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTRUCT VALIDITY; DELUSIONAL DISORDER; DISEASE SEVERITY; EUROPE; EUROPEAN QUALITY OF LIFE QUESTIONNAIRE 5D; FEMALE; HEALTH STATUS; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGICAL RATING SCALE; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; SCORING SYSTEM; VALIDITY; VISUAL ANALOG SCALE; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANXIETY DISORDERS; COMORBIDITY; DELUSIONS; DEPRESSIVE DISORDER; DISABILITY EVALUATION; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SCHIZOTYPAL PERSONALITY DISORDER;

EID: 33947717466     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2006.08.004     Document Type: Article

References (52)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (1994), American Psychiatric Press, Washington, DC
2. American Psychological Association. Standard for educational and psychological tests (1974), American Psychological Association, Washington, DC
3. Angermeyer M.C., Kilian R., and Matschinger H. WHOQOL-100 und WHOQOL-BREF. Handbuch für die deutschsprachige Version der WHO-Instrumente zur Erfassung von Lebensqualität (2000), Hogrefe-Verlag, Göttingen
4. Awad A.G., and Voruganti L.N. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 18 (2004) 877-893
5. Awad A.G., Voruganti L.N., and Heslegrave R.J. Measuring quality of life in patients with schizophrenia. Pharmacoeconomics 11 (1997) 32-47
6. Bobes J., Garcia-Portilla P., Saiz P.A., Bascaran T., and Bousono M. Quality of life measures in schizophrenia. Eur Psychiatry 20 Suppl. 3 (2005) S313-S317
7. Bowling A. Measuring disease (1995), Open University Press, Buckingham
8. Brazier J., Deverill M., Green C., Harper R., and Booth A. A review of the use of health status measures in economic evaluation. Health Technol Assess 3 i-iv (1999) 1-164
9. Brazier J., Roberts J., Tsuchiya A., and Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 13 (2004) 873-884
10. Brooks R. EuroQol: the current state of play. Health Policy 37 (1996) 53-72
11. Ciudad A., Montes J.M., Olivares J.M., and Gomez J.C. Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study. Eur Psychiatry 19 (2004) 358-365
12. Cohen J. Statistical power analysis for the behavioral sciences (1988), Lawrence Earlbaum Associates, Hillsdale, NJ
13. Corrigan P.W., and Buican B. The construct validity of subjective quality of life for the severely mentally ill. J Nerv Ment Dis 183 (1995) 281-285
14. Cronbach L.J., and Meehl P.E. Construct validity in psychological tests. Psychol Bull 52 (1955) 281-302
15. Dernovsek M.Z., Prevolnik Rupel V., Rebolj M., and Tavcar R. Quality of life and treatment costs in schizophrenic outpatients, treated with depot neuroleptics. Eur Psychiatry 16 (2001) 474-482
16. Derogatis L.R. SCL-90-R: administration, scoring and procedures manual (1994), National Computer Systems, Minneapolis, MN
17. Dolan P. Modeling valuations for EuroQol health states. Med Care 35 (1997) 1095-1108
18. Drummond M.F., O'Brien B., Stoddart G.L., and Torrance G.W. Methods for the economic evaluation of health care programmes (1997), Oxford University Press, Oxford, UK
19. EuroQol Group. Complete list of references. EuroQol Group, http://www.euroqol.org.
20. Franz M., Meyer T., Reber T., and Gallhofer B. The importance of social comparisons for high levels of subjective quality of life in chronic schizophrenic patients. Qual Life Res 9 (2000) 481-489
21. Gold M., Siegel J., Russel L., and Weinstein M. Cost-effectiveness in health and medicine (1996), Oxford University Press, New York
22. Green C., Brazier J., and Deverill M. Valuing health-related quality of life. A review of health state valuation techniques. Pharmacoeconomics 17 (2000) 151-165
23. Greiner W., Claes C., Busschbach J.J., and Graf von der Schulenburg J.M. Validating the EQ-5D with time trade off for the German population. Eur J Health Econom 6 (2005) 124-130
24. Herrman H., Hawthorne G., and Thomas R. Quality of life assessment in people living with psychosis. Soc Psychiatry Psychiatr Epidemiol 37 (2002) 510-518
25. Kaiser W., Priebe S., Barr W., Hoffmann K., Isermann M., Roder-Wanner U.U., et al. Profiles of subjective quality of life in schizophrenic in- and out-patient samples. Psychiatry Res 66 (1997) 153-166
26. Karow A., and Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berl) 162 (2002) 3-10
27. Katschnig H. Schizophrenia and quality of life. Acta Psychiatr Scand Suppl (2000) 33-37
28. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 261-276
29. König H.H. Messung von Patientenpräferenzen in der Psychiatrie. Eine Literaturübersicht über den Einsatz von Standard Gamble, Time Trade-Off und Contingent Valuation bei Depression und Schizophrenie. Psychiatr Prax 31 (2004) 118-127
30. König H.H., Bernert S., and Angermeyer M.C. Gesundheitszustand der deutschen Bevölkerung: Ergebnisse einer repräsentativen Befragung mit dem EuroQol-Instrument. Gesundheitswesen 67 (2005) 173-182
31. Lamers L.M., Stalmeier P.F., Krabbe P.F., and Busschbach J.J. Inconsistencies in TTO and VAS V1alues for EQ-5D Health States. Med Decis Making 26 (2006) 173-181
32. Montes J.M., Ciudad A., Gascon J., and Gomez J.C. Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 667-674
33. National Institute of Mental Health. 12-CGI. Clinical global impressions. In: Guy W. (Ed). EDCEU assessment in psychopharmacology (1970), National Institute of Mental Health, Rockville, MD 217-222
34. Patrick D.L., and Deyo R.A. Generic and disease-specific measures in assessing health status and quality of life. Med Care 27 (1989) S217-S232
35. Patrick D.L., and Erickson P. Health status and health policy (1993), Oxford University Press, New York
36. Priebe S., Oliver J.P.J., and Kaiser W. Quality of life and mental health care (1999), Wrightson Biomedical, Petersfield
37. Prieto L., Novick D., Sacristan J.A., Edgell E.T., and Alonso J. A Rasch model analysis to test the cross-cultural validity of the EuroQoL-5D in the Schizophrenia Outpatient Health Outcomes Study. Acta Psychiatr Scand Suppl (2003) 24-29
38. Prieto L., Sacristan J.A., Hormaechea J.A., Casado A., Badia X., and Gomez J.C. Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin 20 (2004) 827-835
39. Rasanen P., Roine E., Sintonen H., Semberg-Konttinen V., Ryynanen O.P., and Roine R. Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review. Int J Technol Assess Health Care 22 (2006) 235-241
40. Revicki D.A., and Kaplan R.M. Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life. Qual Life Res 2 (1993) 477-487
41. Roick C., Deister A., Zeichner D., Birker T., Konig H.H., and Angermeyer M.C. Das Regionale Psychiatriebudget: Ein neuer Ansatz zur effizienten Verknüpfung stationärer und ambulanter Versorgungsleistungen. Psychiatr Prax 32 (2005) 177-184
42. Roick C., Thierfelder K., Heider D., Klemm T., Paschke R., and Angermeyer M.C. Untersuchung der Aussagefähigkeit psychometrischer und präferenzbasierter Lebensqualitätsindizes bei psychisch und somatisch Kranken. Psychiatr Prax 31 (2004) 128-137
43. Sapin C., Fantino B., Nowicki M.L., and Kind P. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes 2 (2004) 20
44. The EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 16 (1990) 199-208
45. The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med 28 (1998) 551-558
46. Torrance G.W. Measurement of health state utilities for economic appraisal. J Health Econ 5 (1986) 1-30
47. van de Willige G., Wiersma D., Nienhuis F.J., and Jenner J.A. Changes in quality of life in chronic psychiatric patients: a comparison between EuroQol (EQ-5D) and WHOQoL. Qual Life Res 14 (2005) 441-451
48. von der Schulenburg J.M., Claes C., Greiner W., and Uber A. Die deutsche Version des Euro-Qol-Fragebogens. Zeitschrift für Gesundheitswissenschaften 6 (1998) 3-20
49. Weinstein M.C., Siegel J.E., Gold M.R., Kamlet M.S., and Russell L.B. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276 (1996) 1253-1258
50. WHOQOL Group. Measuring quality of life: The development of the World Health Organization quality of life Instrument (WHOQOL) (1993), WHO, Geneva
51. Wing J.K., Beevor A.S., Curtis R.H., Park S.B., Hadden S., and Burns A. Health of the Nation Outcome Scales (HoNOS). Research and development. Br J Psychiatry 172 (1998) 11-18
52. World Health Organisation. The ICD-10 classification of mental and behavioral disorders: clinical descriptions and diagnostic guidelines (1992), World Health Organisation, Geneva